Table 2

Association between MetS and IR and cognitive dysfunction

Predictor variablesCognitive status at follow-up
SBT ≥10CFT ≤14SBT ≥10/CFT ≤14
OR*95% CIOR*95% CIOR*95% CI
Individual components of MetS
 BMI (>30 kg/m2)1.220.76–1.941.240.88–1.741.260.70–2.30
 Elevated blood pressure0.880.56–1.381.070.76–1.500.680.38–1.23
 Impaired fasting plasma glucose1.120.76–1.641.441.09–1.911.560.96–2.52
 Low HDL1.010.59–1.741.190.81–1.740.990.47–2.09
 Elevated triglycerides1.250.81–1.910.980.71–1.361.090.61–1.95
Cumulative sum of risk factors for MetS
 0Reference
 10.720.40–1.271.020.65–1.590.720.34–1.56
 20.640.35–1.191.060.66–1.690.600.27–1.38
 31.180.61–2.271.190.70–2.031.020.41–2.52
 40.590.22–1.601.390.71–2.710.660.19–2.33
 52.560.75–8.793.071.09–8.694.351.02–18.6
MetS
 No MetSReference
 Risk factors for MetS with BMI <30 kg/m20.980.65–1.491.080.80–1.460.940.55–1.61
 BMI >30 kg/m2 and <2 risk factors1.110.53–2.331.300.77–2.191.610.69–3.77
 MetS1.280.71–2.291.300.82–1.941.180.55–2.55
IR (HOMA-IR)
 Dichotomized (HOMA-IR >2.6)0.980.64–1.521.471.09–1.991.330.77–2.27
 Continuous (per unit increase)1.050.98–1.131.081.01–1.161.101.01–1.19
  • *ORs were adjusted for age at baseline, smoking history, alcohol consumption, physical activity, education, and hormone replacement therapy.